MX347263B - Metodos para incrementar la produccion o actividad de catalasa. - Google Patents

Metodos para incrementar la produccion o actividad de catalasa.

Info

Publication number
MX347263B
MX347263B MX2012013671A MX2012013671A MX347263B MX 347263 B MX347263 B MX 347263B MX 2012013671 A MX2012013671 A MX 2012013671A MX 2012013671 A MX2012013671 A MX 2012013671A MX 347263 B MX347263 B MX 347263B
Authority
MX
Mexico
Prior art keywords
catalase
activity
production
methods
animal
Prior art date
Application number
MX2012013671A
Other languages
English (en)
Other versions
MX2012013671A (es
Inventor
Paul Middleton Rondo
Impanbutr Nongnuch
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2012013671A publication Critical patent/MX2012013671A/es
Publication of MX347263B publication Critical patent/MX347263B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

La presente invención se refiere a una vitamina D para usarse en la prevención o el tratamiento de una enfermedad o condición causada por la deficiencia de catalasa en un animal que puede beneficiarse de un incremento en la producción de catalasa; donde la vitamina D es administrable al animal en una cantidad de incremento de producción de catalasa de vitamina D; donde el animal es un animal de compañía en envejecimiento en donde la vitamina D es una o más de calcitriol (1a,25-dihidroxivigtamina D3),25(OH) vitamina D3,20-Epi-1a.25(OH) y 1a,24(R)(OH)2D3; y donde la enfermedad o condición es acatalasemia. Una vitamina D como el único ingrediente activo para usarse en la prevención o el tratamiento de una enfermedad o condición causada por la deficiencia de catalasa en un animal que puede beneficiarse de un incremento en la producción de catalasa; donde la vitamina D es administrable al animal en una cantidad de incremento de producción de catalasa de vitamina D; donde el animal es un animal de compañía en envejecimiento; en donde la vitamina D es una o más de calcitriol (1a,25-dihidroxivitamina D3),25(OH)vitamina D320-Epi.1a,25(oh)2D3 Y 1a,24( R) (OH)2D3;y donde la enfermedad o condición es hepatoma.
MX2012013671A 2010-05-26 2011-05-18 Metodos para incrementar la produccion o actividad de catalasa. MX347263B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39637210P 2010-05-26 2010-05-26
PCT/US2011/000891 WO2011149513A1 (en) 2010-05-26 2011-05-18 Methods for increasing the production or activity of catalase

Publications (2)

Publication Number Publication Date
MX2012013671A MX2012013671A (es) 2013-01-24
MX347263B true MX347263B (es) 2017-04-20

Family

ID=45004240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013671A MX347263B (es) 2010-05-26 2011-05-18 Metodos para incrementar la produccion o actividad de catalasa.

Country Status (10)

Country Link
US (1) US20130178450A1 (es)
EP (2) EP2575474B1 (es)
JP (1) JP5901618B2 (es)
CN (1) CN103281903B (es)
AU (1) AU2011258854B2 (es)
CA (1) CA2800167A1 (es)
ES (1) ES2627115T3 (es)
MX (1) MX347263B (es)
RU (1) RU2586910C2 (es)
WO (1) WO2011149513A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5789339B2 (ja) * 2013-01-21 2015-10-07 レジリオ株式会社 アルツハイマー病等を含む神経疾患の１，２５ｄ３−ｍａｒｒｓが関与する治療薬及び治療法
CA2916639C (en) 2013-07-01 2020-10-13 Washington University Human diet equivalent animal feed
US20160085801A1 (en) * 2014-09-24 2016-03-24 Salesforce.Com, Inc. System, method and computer program product for updating database objects with report aggregations
EP3689157A1 (en) * 2019-02-03 2020-08-05 Koninklijke Philips N.V. Recommending ingredients for use in the making of a nutritional preparation, comprising folate
CN113846141A (zh) * 2021-07-26 2021-12-28 浙江工商大学 基于乳液界面能诱导释放的生理毒性快速检测方法及应用
CN113373122A (zh) * 2021-07-29 2021-09-10 辽宁未来生物科技有限公司 一种新型玉米超氧化物歧化酶多酶的制备方法
CN114875077B (zh) * 2022-04-18 2023-09-05 中国科学院天津工业生物技术研究所 一种氧化酶催化羟化维生素d3合成阿法骨化醇及骨化三醇的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102680A1 (en) * 1996-07-03 2002-08-01 Robertson Dan E. Catalases
EP1213970B1 (en) 1999-09-07 2008-06-11 Societe Des Produits Nestle S.A. Method for improving the skin and coat of pets
AU777668B2 (en) 1999-09-22 2004-10-28 Societe Des Produits Nestle S.A. Method for increasing pet activity
EP1155627A1 (en) * 2000-05-18 2001-11-21 Belovo Eggs & Egg Products Eggs with balanced lipid composition
CA2409286C (en) 2000-05-25 2012-05-15 Societe Des Produits Nestle S.A. Dog & cat food compositions having a probiotic lactobacillus strain
WO2001091578A2 (en) 2000-05-26 2001-12-06 Societe Des Produits Nestle S.A. Foodstuff for pets or other animals
GB0027761D0 (en) 2000-11-14 2000-12-27 Nestle Sa Nutritional composition for an immune condition
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
RU2280448C2 (ru) * 2002-11-10 2006-07-27 Институт биофизики клетки РАН Композиция с антиоксидантными свойствами и способ лечения болезней млекопитающих
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement

Also Published As

Publication number Publication date
EP2575474A1 (en) 2013-04-10
EP2575474B1 (en) 2017-04-26
US20130178450A1 (en) 2013-07-11
CN103281903B (zh) 2016-04-20
CA2800167A1 (en) 2011-12-01
MX2012013671A (es) 2013-01-24
JP5901618B2 (ja) 2016-04-13
RU2586910C2 (ru) 2016-06-10
EP2777706A1 (en) 2014-09-17
JP2013528186A (ja) 2013-07-08
CN103281903A (zh) 2013-09-04
WO2011149513A1 (en) 2011-12-01
ES2627115T3 (es) 2017-07-26
RU2012157084A (ru) 2014-08-10
AU2011258854B2 (en) 2016-02-11
EP2575474A4 (en) 2013-10-30
AU2011258854A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
MX347263B (es) Metodos para incrementar la produccion o actividad de catalasa.
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
AU2016216625A1 (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
MX353727B (es) Tratamiento de sinucleinopatias.
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
MX2007008021A (es) Composiciones que incluyen hierro.
MX2011007930A (es) Conjugados de insulina cristalina.
UA107667C2 (uk) Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку
EP2493507A4 (en) ANTAGONISTS AND VARIANTS AX213 AND AX132 PCSK9
MX348898B (es) Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
WO2009111317A3 (en) Endoscopic delivery of red/nir light to the substantia nigra to treat parkinson's disease
TN2012000270A1 (en) Methods and low dose regimens for treating red blood cell disorders
MY173616A (en) Compositions and methods for lowering triglycerides
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
IN2012DN02737A (es)
PH12015500756A1 (en) Methods for enhancing the effect of egcg on mitigating skeletal muscle loss
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
EP2646019A4 (en) PREPARATION AND USE OF (+) - 1- (3,4-DICHLOROPHENYL) -3-AZABICYCLO- [3.1.0] HEXANE IN THE TREATMENT OF DISEASES AFFECTED BY MONOAMINE-TYPE NEUROTRANSMITTERS
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
MX2013006595A (es) Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.
WO2012112340A3 (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
WO2010019212A3 (en) Methods for enhancing energy metabolism
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3

Legal Events

Date Code Title Description
FG Grant or registration